Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
RAPT Therapeutics (RAPT) Stock Price & Analysis
260 Followers
RAPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.98 - $27.35
Previous Close$4.04
Volume542.37K
Average Volume (3M)1.52M
Market Cap
$141.01M
Enterprise Value-$36.30M
Total Cash (Recent Filing)$184.78M
Total Debt (Recent Filing)$7.46M
Price to Earnings (P/E)-1.3
Beta1.38
Next Earnings
Aug 08, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.07
Shares Outstanding34,903,476
10 Day Avg. Volume1,314,140
30 Day Avg. Volume1,515,773
Standard Deviation0.31
R-Squared0.00856
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-23.78
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
$13.80Price Target Upside241.58% Upside
Rating ConsensusHold
Number of Analyst Covering9
RAPT Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRAPT is advancing their clinical programs with promising data on the horizon, as they plan to unblind their Phase 2b atopic dermatitis study and Phase 2a asthma study for a comprehensive analysis of safety and efficacy.
Regulatory EngagementRAPT is proactively engaging with the FDA to resolve a clinical hold, with management confident in the data supporting future development and regulatory discussions.
Strategic PartnershipsRAPT is actively seeking strategic partnerships for their oncology program, signaling confidence in their drug's market potential following encouraging clinical results.
Bears Say
Clinical TrialsClinical success may not translate to stock upside due to potential equity dilution and less efficient R&D execution.
Financial HealthThe company faces a dwindling cash runway that may necessitate additional funding at a high discount, negatively impacting shareholder value.
Regulatory ChallengesFDA's full clinical hold on zelnecirnon due to a serious adverse event creates significant uncertainty for the drug's future.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $3.98 and its highest was $27.35 in the past 12 months.
What is RAPT Therapeutics’s market cap?
Currently, no data Available
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 82 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on May 09, 2024. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$0.809 by $0.019.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -$0.74.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 34,903,477 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$0.809. Following the earnings report the stock price went down -41.604%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Among the largest hedge funds holding RAPT Therapeutics’s share is Perceptive Advisors LLC. It holds RAPT Therapeutics’s shares valued at 53M.
---
RAPT Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.80 (241.58% Upside)
$13.80 (241.58% Upside)
Blogger Sentiment
Bullish
RAPT Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 370.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.81%
12-Months-Change
Fundamentals
Return on Equity
-67.21%
Trailing 12-Months
Asset Growth
-37.25%
Trailing 12-Months
Company Description
RAPT Therapeutics
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
---
RAPT Stock 12 Month Forecast
Average Price Target
$13.80
▲(241.58% Upside)
Technical Analysis
Best Analysts Covering RAPT
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-36.09%
assigned a buy rating 2 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -36.09% per trade.
---